Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria,
published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for …

Mutations in leucine-rich repeat kinase 2 (LRRK2) cause inherited Parkinson disease (PD),
and common variants around LRRK2 are a risk factor for sporadic PD. Using protein–protein …

Although the induction of persistent behavioral alterations by drugs of abuse requires the
regulation of gene transcription, the precise intracellular signaling pathways that are involved …

Objective To investigate the longitudinal dose-effect relationship between dopamine replacement
therapy and impulse control disorders (ICDs) in Parkinson disease (PD). Methods We …

Background Previous overviews suggested that hydroxymethyl glutaryl coenzyme A
reductase inhibitors (statins), but not other lipid-lowering therapy (LLT), may reduce stroke …

Background Genome-wide association studies (GWAS) in Parkinson's disease have increased
the scope of biological knowledge about the disease over the past decade. We aimed to …

Many drugs of abuse exert their addictive effects by increasing extracellular dopamine in
the nucleus accumbens, where they likely alter the plasticity of corticostriatal glutamatergic …

Aims: The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a
chelation strategy aimed at reducing oxidative damage associated with regional iron …

Autosomal-recessive early-onset parkinsonism is clinically and genetically heterogeneous.
The genetic causes of approximately 50% of autosomal-recessive early-onset forms of …

Background Iron content is increased in the substantia nigra of persons with Parkinson’s
disease and may contribute to the pathophysiology of the disorder. Early research suggests that …